TrialDiabetes, obesity & metabolism2025

Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.

Jelle M Beernink et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.